CJEU declines to assess unfriendly SPCs based on third-party MAs in Eli Lilly v. Genentech (C-239/19)
One of the features that render the European Union’s Supplementary Protection Certificate (SPC) unique in comparison to similar legal instruments in other jurisdictions, including the United States and Japan, is that there is no legal provision expressly calling for any specific relationship or agreement between the patent proprietor (and SPC applicant) on the one hand,…